{
  "paper_metadata": {
    "pmid": "36553503",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 17,
        "demographics": "Italian population, specific ages and sexes not detailed",
        "phenotype": "ATTRv amyloidosis with kidney involvement"
      },
      "penetrance_data": {
        "total_carriers_observed": 17,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "uncertain",
          "phenotype_details": "Kidney involvement not specified for individuals",
          "evidence_sentence": "In the present study, we describe trajectories of kidney function over time before and after treatment with gene silencing therapies in a cohort of 17 ATTRv patients with different mutations."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "uncertain",
          "phenotype_details": "Kidney involvement not specified for individuals",
          "evidence_sentence": "The majority of patients had the Val30Met variant (n = 6, approximately 35%) or the Phe64Leu variant (n = 8, 47%)."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "uncertain",
          "phenotype_details": "Kidney involvement not specified for individuals",
          "evidence_sentence": "The remaining patients harbored the Thr59Lys variant (n = 2, 12%), and the Ile68Leu variant (n = 1, 6%)."
        }
      ],
      "functional_data": {
        "summary": "The study suggests that gene-silencing therapies may be safe for renal function in ATTRv amyloidosis.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "medium",
      "source_location": "Results, paragraph 3",
      "additional_notes": "No specific penetrance percentages or detailed individual data were provided.",
      "key_quotes": [
        "Kidney involvement has always been considered a classical feature in ATTRv 'Portuguese' phenotype but, recently, many papers also underlined its occurrence in late-onset patients."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Baseline characteristics of the enrolled patients",
      "variants_extracted": 4
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "medium",
    "challenges": [
      "Limited individual-level data on penetrance and affected status."
    ],
    "notes": "The paper provided a general overview of variants but lacked detailed penetrance statistics."
  }
}